MYELODYSPLASTIC SYNDROME COEXISTING WITH ACUTE LYMPHOBLASTIC LEUKAEMIA

AN STARK, CS SCOTT, B BHATT, BE ROBERTS

From the Department of Haematology, Cookridge Hospital, Leeds

SUMMARY  A 55 year old woman developed chronic myelomonocytic leukaemia (CMML) one year after she had been successfully treated for acute lymphoblastic leukaemia (ALL). When the ALL relapsed the CMML remitted only to return with further remission of the ALL. A consistent chromosomal abnormality, t(4;11), was present during both CMML and ALL phases.

Case report

A 55 year old woman presented in February 1983 with left hypochondrial pain, which was diagnosed as splenic infarction. She was otherwise entirely well, and there were no relevant medical or family histories. Examination showed minimal cervical lymphadenopathy, together with hepatomegaly (3 cm) and splenomegaly (4 cm). Haemoglobin was 12·6 g/dl, platelets 67 x 10^9/l, and white cells 4·8 x 10^9/l (50% neutrophils, 24% monocytes, 22% lymphocytes, 3% myelocytes, 1% blasts). Bone marrow aspirate showed >90% blasts (mostly small), with a high nuclear:cytoplasmic ratio and indistinct nucleoli. The blasts were negative with Sudan black, peroxidase, and alpha-naphthyl-acetate-esterase (ANAE) and reacted strongly with both antiterminal deoxy-nucleotidyl transferase anti-Tot and J5 (common acute lymphoblastic leukaemia antigen; CALLA) monoclonal antibody. Granulopoiesis, erythropoiesis, and megakaryopoiesis were reduced but were of normal morphology. Serum lysozyme activity was 460 U/ml (normal range 200–500 U/ml). Chromosomal analysis was not performed at this time. Common acute lymphoblastic leukaemia (C-ALL), was diagnosed and she received daunorubicin, vincristine, prednisolone, and L-asparaginase. Bone marrow aspirate at the end of week three showed complete remission.

She received further chemotherapy, but in April was noted to have an absolute monocytosis of 3·6 x 10^9/l (total white cells 8·5 x 10^9/l). As she continued to have painful splenomegaly a further bone marrow aspiration was performed, which showed normal morphology in all three myeloid cell lines and confirmed continuing complete remission. She received cranial irradiation uneventfully and was started on maintenance chemotherapy, but the splenomegaly persisted, as did the monocytosis, which was between 3–4 x 10^9/l. A repeat bone marrow aspiration in early June showed normal morphology in all cell lines, though myelopoiesis was left shifted and 5% of nucleated cells were monocytes. Occasional ring sideroblasts were also seen on the Perl's iron stain but none of these features was thought to be particularly abnormal given the stage of her disease and treatment. More chemotherapy was given, but the spleen remained palpable. A bone marrow aspirate taken in December showed, apart from granulocytic hyperplasia with maturation arrest, normal erythropoiesis and megakaryopoiesis, and the peripheral blood monocyte count was 1·4 x 10^9/l (Fig. 1).

In February 1984 while maintenance chemotherapy was still being given, occasional agranular neutrophils were noted in the peripheral blood, with the monocyte count ranging between 1·0–2·0 x 10^9/l. A bone marrow aspiration performed in early March was hypercellular with dysplastic erythropoiesis. Granulopoiesis was left shifted, with many agranular and hypogranular forms present, and abnormal megakaryocytes were also noted. Monocytes comprised 10% of nucleated cells, and the serum lysozyme activity was 1350 U/ml. Chromosomal analysis of bone marrow cells, using methotrexate synchronisation and G banding, showed a 46 XX t(4;11), (q21;q23) karyotype in five of 23 metaphases examined. Chronic myelomonocytic leukaemia (CMML) was diagnosed.

Over the next two weeks her spleen enlarged considerably and was irradiated because of pain. This produced only temporary improvement, however,
and by April the spleen was palpable 17 cm below the left costal margin. At the same time, blasts were noted in both the peripheral blood and bone marrow aspirate (95%) with virtually absent erythropoiesis, myelopoiesis, and megakaryopoiesis. Immunologically, the blasts were CALLA+, TdT+, My906−, and UCHM1−, consistent with relapsed C-ALL. The serum lysozyme concentration had fallen to 610 U/ml. Cytogenetic analysis of bone marrow aspirate continued to show a t(4;11) translocation plus a deletion of chromosomes 3, 5, and 7. Reinduction chemotherapy was given with vincristine and prednisolone, with improvement both in symptoms and spleen size. As the peripheral blood blast count decreased, however, the monocyte count increased and the lysozyme activity rose to 2100 U/ml. Bone marrow at the end of reinduction was consistent with CMML, with no evidence of ALL.

In July her spleen once again increased in size, and a bone marrow aspirate showed relapsed C-ALL with 45% blasts. Serum lysozyme activity was 1220 U/ml (Fig. 2). Chromosomal analysis of bone marrow aspirate again showed a 43 XX t(4;11), (q21;q23), −3, −5, −7 karyotype. Despite further salvage treatment she did not achieve complete remission and died in November 1984 with signs of spinal cord compression. Post mortem examination showed infiltration of the spinal cord, brain, liver, spleen, and kidneys with malignant lymphoblasts.

**Discussion**

In this patient myelodysplastic syndrome, classified by FAB criteria as CMML, coexisted with both morphologically and immunologically confirmed C-ALL. When the ALL was in remission the CMML became dominant and the serum lysozyme activity increased while, in contrast, relapses of the ALL paralleled decreasing serum lysozyme activity. A consistent chromosomal abnormality was present both when the ALL was in relapse and also when it was in remission and CMML was present, suggesting that the two diseases were clonal and arose from a common malignant stem cell. In this respect it is interesting that a peripheral blood monocytosis was noted at first presentation of the ALL, even though the bone marrow did not show typical myelodysplastic changes until a year later. Chromosomal abnormalities affecting t(4;11), (q21;q23), as in this case, are associated with ALL both with and without subsequent
monocytic transformation. Most of these cases of ALL have, however, been of Null phenotype with only one previous case of t(4;11) in C-ALL. Furthermore, when monocytic transformation of these cases of ALL has occurred, it has been of the acute myelomonocytic or monocytic variety (M4, M5), which this patient did not have.

Myeloproliferative disease and apparent lymphoid malignancy are known to occur together in chronic myeloid leukaemia with lymphoid blast crisis (CML-LBC). During LBC the CML is not often apparent, even though the blast cells usually still show the Ph chromosome. Successful treatment of LBC results in remission of the ALL, but not the CML, which invariably reappears. Our case would appear to be analogous to CML-LBC, though this situation has not, to our knowledge, previously been reported in myeloid dysplasia. It has been recently suggested that the translocation t(4;11) occurs in a pluripotential target cell, which could explain the mixed lymphoid and monocytic components often seen in these cases. As the c-oncogene c-ets is thought to lie in the region of the breakpoint in t(4;11), it is tempting to speculate that it may participate in the malignant transformation, analogous to c-abl in CML.

References


3 Levin MD, Michael PM, Garson OM, Tiedmann K, Firkin FC. Clinicopathological characteristics of acute lymphoblastic leukaemia with the 4;11 chromosome translocation. Pathology 1984;16:63–6.


Request for reprints to: Dr CS Scott, Department of Haematology, Regional Radiotherapy Centre, Cookridge Hospital, Leeds LS16 6QB, England.
Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia.
A N Stark, C S Scott, B Bhatt and B E Roberts

doi: 10.1136/jcp.39.7.728

Updated information and services can be found at:
http://jcp.bmj.com/content/39/7/728

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/